Cargando…

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

CONTEXT: Denosumab and zoledronic acid (ZOL) are parenteral treatments for patients with osteoporosis. OBJECTIVE: The objective of the study was to compare the effect of transitioning from oral bisphosphonates to denosumab or ZOL on bone mineral density (BMD) and bone turnover. DESIGN AND SETTING: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miller, P. D., Pannacciulli, N., Brown, J. P., Czerwinski, E., Nedergaard, B. S., Bolognese, M. A., Malouf, J., Bone, H. G., Reginster, J.-Y., Singer, A., Wang, C., Wagman, R. B., Cummings, S. R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971333/ https://www.ncbi.nlm.nih.gov/pubmed/27270237 http://dx.doi.org/10.1210/jc.2016-1801

Ejemplares similares

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
por: Papapoulos, S., et al.
Publicado: (2015)

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
por: Bone, Henry G., et al.
Publicado: (2013)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis
por: Kong, Sung Hye, et al.
Publicado: (2022)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a ‘real-life’ study
por: Fraser, T. R., et al.
Publicado: (2019)

Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
por: Reginster, J. Y., et al.
Publicado: (2014)

Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
por: Karlsson, L., et al.
Publicado: (2015)

Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
por: Kang, Taewook, et al.
Publicado: (2022)

Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
por: Spangler, Leslie, et al.
Publicado: (2023)

Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management
por: Dalle Carbonare, Luca, et al.
Publicado: (2010)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
por: Yassin, Mohamed A., et al.
Publicado: (2020)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
por: You, Ruxu, et al.
Publicado: (2022)

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
por: Ferrari, S, et al.
Publicado: (2019)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
por: Benjamin, Biju, et al.
Publicado: (2016)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
por: Słopień, Radosław, et al.
Publicado: (2017)

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡
por: Xue, Fei, et al.
Publicado: (2013)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
por: Miyoshi, Arina, et al.
Publicado: (2020)

A reappraisal of generic bisphosphonates in osteoporosis
por: Kanis, J. A., et al.
Publicado: (2011)

Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates?
por: Bandeira, Francisco, et al.
Publicado: (2020)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
por: Cairoli, Elisa, et al.
Publicado: (2015)

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022)

Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients
por: Shimizu, Tomohiro, et al.
Publicado: (2021)

Modeling‐Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
por: Dempster, David W, et al.
Publicado: (2020)

Study on the role of zoledronic acid in treatment of postmenopausal osteoporosis women
por: Chao, Ma, et al.
Publicado: (2013)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qtmucsju3ancng2013l7plllrf